Carrier 62MC Instrukcja Użytkownika Pobierz pdf (Strona 9)

8 Journal of Oncology

[2] M. S Gordon, D. Matei, C. Aghajanian, et al., “Clinical activ-

ity of pertuzumab (rhuMab 2C4) in advanced, refractory

or recurrent ovarian cancer (OC), and the role of HER2

activation status,” Journal of Clinical Oncology, vol. 23, no.

16S, 2005, abstract 5051.

[3] M. V. Seiden, H. A. Burris, U. Matulonis, et al., “A phase II

trial of EMD72000 (matuzumab), a humanized anti-EGFR

monoclonal antibody, in patients with platinum-resistant

ovarian and primary peritoneal malignancies,” Gynecologic

Oncology, vol. 104, no. 3, pp. 727–731, 2007.

[4]E.M.Posadas,M.S.Liel,V.Kwitkowski,etal.,“Aphase

II and pharmacodynamic study of geﬁtinib in patients with

refractory or recurrent epithelial ovarian cancer,” Cance r, vol.

109, no. 7, pp. 1323–1330, 2007.

[5] A. N. Gordon, N. Finkler, R. P. Edwards, et al., “Eﬃcacy

and safety of erlotinib HCl, an epidermal growth factor

receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients

with advanced ovarian carcinoma: results from a phase

II multicenter study,” International Journal of Gynecological

Cancer, vol. 15, no. 5, pp. 785–792, 2005.

[6] S. Campos, O. Hamid, M. V. Seiden, et al., “Multicenter, ran-

domized phase II trial of oral CI-1033 for previously treated

advanced ovarian cancer,” Journal of Clinical Oncology, vol.

23, no. 24, pp. 5597–5604, 2005.

[7]R.A.Burger,M.W.Sill,B.J.Monk,B.E.Greer,andJ.

I. Sorosky, “Phase II trial of bevacizumab in persistent or

recurrent epithelial ovarian cancer or primary peritoneal

cancer: a Gynecologic Oncology Group study,” Journal of

Clinical Oncology, vol. 25, no. 33, pp. 5165–5171, 2007.

[8] S. A. Cannistra, U. A. Matulonis, R. T. Penson, et al.,

“Phase II study of bevacizumab in patients with platinum-

resistant ovarian cancer or peritoneal serous cancer,” Journal

of Clinical Oncology, vol. 25, no. 33, pp. 5180–5186, 2007.

[9] A. A. Garcia, H. Hirte, G. Fleming, et al., “Phase II

clinical trial of bevacizumab and low-dose metronomic oral

cyclophosphamide in recurrent ovarian cancer: a trial of the

California, Chicago, and Princess Margaret Hospital Phase II

Consortia,” Journal of Clinical Oncology,vol.26,no.1,pp.

76–82, 2008.

[10] J. D. Wright, A. Hagemann, J. S. Rader, et al., “Bevacizumab

combination therapy in recurrent, platinum-refractory,

epithelial ovarian carcinoma,” Cancer, vol. 107, no. 1, pp. 83–

89, 2006.

[11] J. C. Chura, K. Van Iseghem, L. S. Downs Jr., L. F. Carson,

andP.L.Judson,“Bevacizumabpluscyclophosphamidein

heavily pretreated patients with recurrent ovarian cancer,”

Gynecologic Oncology, vol. 107, no. 2, pp. 326–330, 2007.

[12] H. S. Nimeiri, A. M. Oza, R. J. Morgan, et al., “Eﬃcacy

and safety of bevacizumab plus erlotinib for patients with

recurrent ovarian, primary peritoneal, and fallopian tube

cancer: a trial of the Chicago, PMH, and California Phase II

Consortia,” Gy necologic Oncology, vol. 110, no. 1, pp. 49–55,

2008.

[13] B.J.Monk,E.Han,C.A.Josephs-Cowan,G.Pugmire,and

R. A. Burger, “Salvage bevacizumab (rhuMAB VEGF)-based

therapy after multiple prior cytotoxic regimens in advanced

refractory epithelial ovarian cancer,” Gynecologic Oncology,

vol. 102, no. 2, pp. 140–144, 2006.

[14] F. Simpkins, J. L. Belinson, P. G. Rose, et al., “Avoiding

bevacizumab related gastrointestinal toxicity for recurrent

ovarian cancer by careful patient screening,” Gynecologic

Oncology, vol. 107, no. 1, pp. 118–123, 2007.

[15] K. F. McGonigle, H. G. Muntz, J. L. Vuky, et al., “A phase

II prospective study of weekly topotecan and bevacizumab

in platinum refractory ovarian cancer or peritoneal cancer,”

Journal of Clinical Oncology, vol. 26, 2008, abstract 5551.

[16] J. P. Micha, B. H. Goldstein, M. A. Rettenmaier, et al., “A

phase II study of outpatient ﬁrst-line paclitaxel, carboplatin,

and bevacizumab for advanced-stage epithelial ovarian,

peritoneal, and fallopian tube cancer,” International Journal

of Gynecolog ical Cancer, vol. 17, no. 4, pp. 771–776, 2007.

[17]N.S.Azad,E.M.Posadas,V.E.Kwitkowski,etal.,“Com-

bination targeted therapy with sorafenib and bevacizumab

results in enhanced toxicity and antitumor activity,” Journal

of Clinical Oncology, vol. 26, no. 22, pp. 3709–3714, 2008.

[18] R. T. Penson, S. Cannistra, M. V. Seiden, et al., “Phase II

study of carboplatin, paclitaxel and bevacizumab as ﬁrst line

therapy and consolidation for advanced mullerian tumors,”

Journal of Clinical Oncology

, vol. 24, no. 18S, 2006, abstract

5020.

[19] S. C. Campos, D. S. Dizon, S. A. Cannistra, et al., “Safety

of maintenance bevacizumab after ﬁrst-line chemotherapy

for advanced ovarian mullerian cancers,” Journal of Clinical

Oncology, vol. 25, no. 18S, 2007, abstract 5517.

[20] S. M. Campos, R. T. Penson, U. Matulonis, et al., “STAC: a

randomized phase II trial of avastin or avastin + erlotinib as

ﬁrst line consolidation chemotherapy after standard therapy,”

Brit ish Gynecological Society Meeting, 2008, abstract 93.

[21] U. A. Matulonis, S. Berlin, P. Ivy, et al., “Cediranib, an

oral inhibitor of vascular endothelial growth factor receptor

kinases, is an active drug in recurrent epithelial ovarian,

fallopian tube and peritoneal cancer,” Journal of Clinical

Oncology, vol. 27, no. 33, pp. 5601–5606, 2009.

[22] H. W. Hirte, L. Vidal, G. F. Fleming, et al., “A phase II study

of cediranib (AZD2171) in recurrent or persistent ovarian,

peritoneal or fallopian tube cancer. Final results of a PMH,

Chicago and California consortia trial,” Journal of Clinical

Oncology, vol. 26, no. 298S, 2008, abstract 5521.

[23] R. Buckstein, R. M. Meyer, L. Seymour, et al., “Phase II testing

of sunitinib: the National Cancer Institute of Canada Clinical

Trials Group IND Program Trials IND. 182–185,” Current

Oncology, vol. 14, no. 4, pp. 154–161, 2007.

[24] M. Friedlander, K. C. Hancock, B. Benigno, et al., “Pazopanib

(GW 786034) is active in women with advanced epithelial

ovarian, fallopian tube, and peritoneal cancers: results of a

phase II study,” Journal of Clinical Oncology, vol. 25, no. 18S,

2007, abstract 5561.

[25] J. J. Biagi, A. M. Oza, R. Grimshaw, et al., “A phase II

study of sunitinib (SU11248) in patients with recurrent

epithelial ovarian cancer, fallopian tube or primary peri-

toneal carcinoma-NCIC CTG IND 185,” Journal of Clinical

Oncology, vol. 26, 2008, abstract 5522.

[26] D. Matei, M. W. Still, K. DeGeest, et al., “Phase II study of

sorafenib in persistent or recurrent epithelial ovarian cancer(

EOC) or primary peritoneal cancer ( PPC): a Gynecology

Oncology Group (GOG) study,” Journal of Clinical Oncology,

vol. 26, 2008, abstract 5537.

[27] E. J. Battegay, “Angiogenesis: mechanistic insights, neovascu-

lar diseases, and therapeutic prospects,” Journal of Molecular

Medicine, vol. 73, no. 7, pp. 333–346, 1995.

[28] J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid

and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31,

1995.

[29] H. C. Hollingsworth, E. C. Kohn, S. M. Steinberg, M. L.

Rothenberg, and M. J. Merino, “Tumor angiogenesis in

advanced stage ovarian carcinoma,” The American Journal of

Pathology, vol. 147, no. 1, pp. 33–41, 1995.

1 2 3 4 5 6 7 8 9 10 11 12

Komentarze do niniejszej Instrukcji

Brak uwag

Carrier 62MC Instrukcja Użytkownika Strona 9

Komentarze do niniejszej Instrukcji

Powiązane produkty i podręczniki dla Nie Carrier 62MC